Delivery Time: ~7 days
What is Urispas?
Urispas is a synthetically derived urinary tract spasmolytic. It is available in tablets for oral administration, each containing Flavoxate hydrochloride as main ingredient. It works by relaxing smooth muscles of the bladder helping to reduce urine leakage, urinary urgency and bladder spasms. However it doesn’t treat the underlying condition, such as urinary infection and inflammation, though it is administered concomitantly with definitive treatment.
When is Urispas indicated?
Urispas is indicated for the symptomatic treatment of certain bladder infection and urinary tract symptoms, and namely dysuria, nocturia, urinary urgency, suprapubic pain, urinary incontinence and frequency associated with cystitis, urethritis, prostatitis and urethrocystitis. The drug is intended for use in adults and children of 12 years old and upwards.
How to take Urispas?
Urispas dosage is calculated by physician according to the type and severity of symptoms. In most cases one or two tablets are administered 3-4 times a day. The dose can be then lowered with the improvement of symptoms and beneficial response to therapy. Duration of treatment depends on the underlying condition and should be determined by the doctor. Do not increase your dosage or your dosing frequency if otherwise approved by your physician as it may increase the risk of side effects.
What are Urispas side effects?
Urispas is generally well tolerated, though as the case may be, it can provoke gastrointestinal upset, headache, dizziness, drowsiness, dry mouth, nervousness, light sensitivity, ophthalmalgia and blurred vision. In case these side effects manifest or if you notice any other adverse reactions not listed above, contact your physician or pharmacist. If you experience drowsiness or altered vision, hold back from operating machinery or motor vehicles and participating in activities requiring alertness.
When is Urispas contraindicated?
Urispas is contraindicated to people hypersensitive to Flavoxate hydrochloride as well as to patients with such obstructive conditions as gastrointestinal hemorrhage, lower urinary tract obstructive uropathy, duodenal or pyloric obstruction, achalasia and ileus. Caution should be exercised when administering to patients with glaucoma, pregnant and nursing women. The drug shouldn’t be administered to pediatric patients under 12 years of age.